Monica Toft Hannani

Monica Toft Hannani

Auto-generated profile, based on publicly available information

Monica Toft Hannani

Nordic Bioscience A/S, Herlev, Denmark

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2022 in Nature
Verified
Journal Article
Closed access
PDF file
CKChristoph Kuppe
Christoph Kuppe
RFRicardo O. Ramirez Flores
Ricardo O. Ramirez Flores
ZLZhijian Li
Zhijian Li
SHSikander Hayat
Sikander Hayat
RLRebecca T. Levinson
Rebecca T. Levinson
RKRafael Kramann
Rafael Kramann

4 February 2022 in Science Advances
Verified
Journal Article
Open access
AMAnne von Mässenhausen
Anne von Mässenhausen
NGNadia Zamora Gonzalez
Nadia Zamora Gonzalez
FMFrancesca Maremonti
Francesca Maremonti
ABAlexia Belavgeni
Alexia Belavgeni
WTWulf Tonnus
Wulf Tonnus
ALAndreas Linkermann
Andreas Linkermann
Dexamethasone is widely used as an immunosuppressive therapy and recently as COVID-19 treatment. Here, we demonstrate that dexamethasone sensitizes to ferroptosis, a form of iron-catalyzed necrosis, previously suggested to contribute to diseases such as acute kidney injury, myocardial infarction, and stroke, all of which are triggered by glutathione (GSH) depletion. GSH levels were significantly decreased by dexamethasone. Mechanistically, we identified that dexamethasone up-regulated the GSH metabolism regulating protein dipeptidase-1 (DPEP1) in a glucocorticoid receptor (GR)–dependent manner. DPEP1 knockdown reversed the phenotype of dexamethasone-induced ferroptosis sensitization. Ferroptosis inhibitors, the DPEP1 inhibitor cilastatin, or genetic DPEP1 inactivation reversed the dexamethasone-induced increase in tubular necrosis in freshly isolated renal tubules. Our data indicate that dexamethasone sensitizes to ferroptosis by a GR-mediated increase in DPEP1 expression and GSH depletion. Together, we identified a previously unknown mechanism of glucocorticoid-mediated sensitization to ferroptosis bearing clinical and therapeutic implications.

14 February 2024 in Expert Review of Molecular Diagnostics
Verified
Journal Article
Open access
MHMonica T. Hannani
Monica T. Hannani
CTChristian S. Thudium
Christian S. Thudium
MKMorten A. Karsdal
Morten A. Karsdal
CLChristoph Ladel
Christoph Ladel
AMAli Mobasheri
Ali Mobasheri
ABAnne-Christine Bay-Jensen
Anne-Christine Bay-Jensen
Osteoarthritis (OA) affects over 500 million people worldwide. OA patients are symptomatically treated, and current therapies exhibit marginal efficacy and frequently carry safety-risks associated with chronic use. No disease-modifying therapies have been approved to date leaving surgical joint replacement as a last resort. To enable effective patient care and successful drug development there is an urgent need to uncover the pathobiological drivers of OA and how these translate into disease endotypes. Endotypes provide a more precise and mechanistic definition of disease subgroups than observable phenotypes, and a panel of tissue- and pathology-specific biochemical markers may uncover treatable endotypes of OA. We have searched PubMed for full-text articles written in English to provide an in-depth narrative review of a panel of validated biochemical markers utilized for endotyping of OA and their association to key OA pathologies. As utilized in IMI-APPROACH and validated in OAI-FNIH, a panel of biochemical markers may uncover disease subgroups and facilitate the enrichment of treatable molecular endotypes for recruitment in therapeutic clinical trials. Understanding the link between biochemical markers and patient-reported outcomes and treatable endotypes that may respond to given therapies will pave the way for new drug development in OA.

16 December 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
FSFelix Schreibing
Felix Schreibing
MHMonica T. Hannani
Monica T. Hannani
HKHyojin Kim
Hyojin Kim
JNJames S. Nagai
James S. Nagai
FTFabio Ticconi
Fabio Ticconi
RKRafael Kramann
Rafael Kramann
Introduction: SARS-CoV-2 infection results in varying disease severity, ranging from asymptomatic infection to severe illness. A detailed understanding of the immune response to SARS-CoV-2 is critical to unravel the causative factors underlying differences in disease severity and to develop optimal vaccines against new SARS-CoV-2 variants.Methods: We combined single-cell RNA and T cell receptor sequencing with CITE-seq antibodies to characterize the CD8+ T cell response to SARS-CoV-2 infection at high resolution and compared responses between mild and severe COVID-19.Results: We observed increased CD8+ T cell exhaustion in severe SARS-CoV-2 infection and identified a population of NK-like, terminally differentiated CD8+ effector T cells characterized by expression of FCGR3A (encoding CD16). Further characterization of NK-like CD8+ T cells revealed heterogeneity among CD16+ NK-like CD8+ T cells and profound differences in cytotoxicity, exhaustion, and NK-like differentiation between mild and severe disease conditions.Discussion: We propose a model in which differences in the surrounding inflammatory milieu lead to crucial differences in NK-like differentiation of CD8+ effector T cells, ultimately resulting in the appearance of NK-like CD8+ T cell populations of different functionality and pathogenicity. Our in-depth characterization of the CD8+ T cell-mediated response to SARS-CoV-2 infection provides a basis for further investigation of the importance of NK-like CD8+ T cells in COVID-19 severity.

25 August 2025 in Expert Review of Molecular Diagnostics
Verified
Journal Article
Closed access
CTChristian S. Thudium
Christian S. Thudium
MHMonica Toft Hannani
Monica Toft Hannani
JCJamie E. Collins
Jamie E. Collins
FRFrank W. Roemer
Frank W. Roemer
VKVirginia B. Kraus
Virginia B. Kraus
ABAnne-Christine Bay-Jensen
Anne-Christine Bay-Jensen
Osteoarthritis (OA) involves an inflammatory component, presenting as synovitis and systemic low-grade inflammation. Preliminary evidence suggests that anti-inflammatory treatments may offer symptomatic and structural benefits in OA. More targeted approaches have been proposed and tested, but the means of identifying the clinical and molecular characteristics of patients with an inflammatory subtype remains unclear. Emerging evidence suggests that subsets of OA patients with significant inflammatory features, such as elevated systemic and synovial cytokine levels (e.g. IL-1, TNF-α), imaging confirmed synovitis, or tissue remodeling biomarker signatures may respond more favorably to anti-inflammatory treatments. We provide a perspective on recent evidence supporting the existence of a clinically actionable inflammatory molecular endotype of OA. We integrate key advances from recent clinical studies, biomarker consortium datasets and imaging models, to outline potential tools for single-patient endotyping, and highlight practical considerations for recognizing an inflammatory endotype in the clinical trial setting. Challenges remain in standardizing tools for identifying these patients. Current methodology, including imaging and soluble biomarkers, are not yet widely adopted in clinical practice. An improved understanding of the inflammatory endotype will be key for improving clinical trial design and identifying patient subpopulations more likely to benefit from targeted treatment.

3 March 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
FSFelix Schreibing
Felix Schreibing
MHMonica Hannani
Monica Hannani
FTFabio Ticconi
Fabio Ticconi
EFEleanor Fewings
Eleanor Fewings
JNJames S Nagai
James S Nagai
RKRafael Kramann
Rafael Kramann
The current COVID-19 pandemic represents a global challenge. A better understanding of the immune response against SARS-CoV-2 is key to unveil the differences in disease severity and to develop future vaccines targeting novel SARS-CoV-2 variants. Feature barcode technology combined with CITE-seq antibodies and DNA-barcoded peptide-MHC I Dextramer reagents enabled us to identify relevant SARS-CoV-2-derived epitopes and compare epitope-specific CD8 + T cell populations between mild and severe COVID-19. We identified a strong CD8 + T cell response against an S protein-derived epitope. CD8 + effector cells in severe COVID-19 displayed hyperactivation, T cell exhaustion and were missing characteristics of long-lived memory T cells. We identify A*0101 WTAGAAAYY as an immunogenic CD8 + T cell epitope with the ability to drive clonal expansion. We provide an in-depth characterization of the CD8 + T cell-mediated response to SARS-CoV-2 infection which will be relevant for the development of molecular and targeted therapies and potential adjustments of vaccination strategies.